MicroPort VisionSecures $590 Million Investment, MicroPort Medical's Stake Rises to Over 85%

MicroPort Medical(00853) announced that on March 30, 2021, MicroPort VisionCare, the Company’s wholly-owned subsidiary MicroPort Investment, and Wangdaotong Biotechnology entered into an agreement with investors regarding capital increase.

MicroPort Investment, Wangdaotong Biotechnology, and the second investor each agreed to inject a total of RMB 385 million into MicroPort Vision. Among this, MicroPort Investment injected RMB 350 million. Upon completion of the capital increase, MicroPort Investment’s shareholding increased to 85.0467%.

MicroPort VisionCare is currently a subsidiary in which the Group holds a 70% equity interest. It is primarily engaged in the research and development, manufacturing, and sales of ophthalmic medical products for diagnosis, treatment, and care, as well as the provision of related services.

Wangdao Tong Biotechnology is primarily engaged in investment holding activities and is wholly owned by Executive Director Chang Zhaohua.